Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naive WM

Key Findings

• ●Novel fixed-duration combination of ibrutinib + venetoclax in treatment-naive WM
• ●Aims to achieve deep responses with time-limited therapy
• ●Represents shift toward combination approaches

Referenced in (1 disease)

1. passsource metadataJun 1, 2026, 04:40 PMby pubmed-api

   Stored DOI was incorrect; corrected to the PubMed-registered DOI (verified to resolve to this article).

   tools: pubmed.esummary, crossref.works